natgillin/translations-raw huggingface dataset:
Table 1: Percentage of patients a responding by treatment group and phase in the Moderately Emetogenic Chemotherapy study versus ondansetron 
Preglednica 1: Odstotek bolnikov a, ki reagirajo na zdravljenje glede na vrsto in stopnjo zdravljenja v študiji zmerno emetogene kemoterapije v primerjavi z ondansetronom
Age does not affect the pharmacokinetics of palonosetron. 
Starejša populacija Starost ne vpliva na farmakokinetiko palonosetrona.
In two randomised, double-blind studies with a total of 1,132 patients receiving moderately emetogenic chemotherapy that included cisplatin ≤50 mg/m 2, carboplatin, cyclophosphamide ≤1,500 mg/m 2 and doxorubicin >25 mg/m2, palonosetron 250 micrograms and 750 micrograms were compared with ondansetron 32 mg (half-life 4 hours) or dolasetron 100 mg (half-life 7.3 hours) administered intravenously on Day 1, without dexamethasone. 
≤1500 mg/m2 in doksorubicin >25 mg/m2, so primerjali odmerka palonosetrona 250 mikrogramov in 750 mikrogramov v primerjavi z ondansetronom 32 mg (razpolovni čas 4 ure) ali dolasetronom 100 mg (razpolovni čas 7,3 ure), danih intravensko prvi dan kemoterapije, brez deksametazona.
PK parameters expressed as Arithmetic mean (SD) Clearance and Volume of distribution in paediatric patients were calculated weight-adjusted from both 10 μg /kg and 20 μg /kg dose groups combined. 
Očistek in volumen porazdelitve pri pediatričnih bolnikih sta bila izračunana za skupino, združeno iz skupin z odmerkoma 10 µg /kg in 20 µg /kg, popravljeni za telesno maso.
Table 2: Percentage of patients a responding by treatment group and phase in the Moderately Emetogenic Chemotherapy study versus dolasetron 
Preglednica 2: Odstotek bolnikov a, ki reagirajo na zdravljenje glede na vrsto in stopnjo zdravljenja v študiji zmerno emetogene kemoterapije v primerjavi z dolasetronom
Palonosetron Hospira 250 micrograms solution for injection palonosetron (as hydrochloride) 
Palonosetron Hospira 250 mikrogramov raztopina za injiciranje palonosetron (v obliki palonosetronijevega klorida)
Palonosetron 250 micrograms (n= 223) 
Palonosetron 250 mikrogramov (n = 223)
Table 3: Percentage of patients a responding by treatment group and phase in the Highly Emetogenic Chemotherapy study versus ondansetron 
Preglednica 3: Odstotek bolnikov a, ki reagirajo na zdravljenje, glede na vrsto zdravljenja in stopnjo zdravljenja v študiji visoko emetogene kemoterapije v primerjavi z ondansetronom
• The active substance is palonosetron (as hydrochloride). 
Zdravilna učinkovina je palonosetron (v obliki palonosetronijevega klorida).
Each ml of solution contains 50 micrograms palonosetron (as hydrochloride). 
En ml raztopine vsebuje 50 mikrogramov palonosetrona (v obliki palonosetronijevega klorida).
How to store Palonosetron Hospira 
Kako uporabljati zdravilo Palonosetron Hospira
What Palonosetron Hospira contains 
Kaj vsebuje zdravilo Palonosetron Hospira
• coughing or shortness of breath 
• kašelj ali kratka sapa
Palonosetron Hospira250 micrograms solution for injection. 
Palonosetron Hospira 250 mikrogramov raztopina za injiciranje
Palonosetron Hospira 250 micrograms solution for injection palonosetron 
Palonosetron Hospira 250 mikrogramov raztopina za injiciranje palonosetron
• motion sickness 
• omotica
Palonosetron 250 micrograms (n= 185) 
Palonosetron 250 mikrogramov (n = 185)
Other medicines and Palonosetron Hospira 
Shranjevanje zdravila Palonosetron Hospira
• dizziness 
• driska.
Single use only 
intravenska uporaba samo za enkratno uporabo
Common ARs (≥1/100 to<1/10) 
Vrsta organskega sistema pogosti neželeni učinki (≥1/100 do<1/10)
Asthenia, pyrexia, fatigue, feeling hot, influenza like illness 
Splošne težave in spremembe na mestu aplikacije astenija, zvišana telesna temperatura, utrujenost, občutek vročine, gripi podobna bolezen reakcija na mestu injiciranja*
• Keep this leaflet. 
• srbeč kožni izpuščaj
Elimination 
• zaprtje
haloperidol, chlorpromazine, quetiapine, thioridazine, domperidone; 
Bolezni dihal, prsnega koša in mediastinalnega prostora kašelj, dispnea, epistaksa
• if you are using Palonosetron Hospira in addition to other medicines that may induce an abnormal heart rhythm such as amiodarone, nicardipine, quinidine, moxifloxacin, erythromycin, 
Preden boste prejeli zdravilo Palonosetron Hospira se posvetujte z zdravnikom ali farmacevtom: - če imate akutno zaporo črevesa ali anamnezo ponavljajočih se zaprtij; - če poleg zdravila Palonosetron Hospira uporabljate druga zdravila, ki lahko povzročijo motnje srčnega ritma, na primer amiodaron, nikardipin, kinidin, moksifloksacin, eritromicin, haloperidol, klorpromazin, kvetiapin, tioridazin, domperidon; - če imate osebno ali družinsko anamnezo sprememb srčnega ritma (podaljšanega intervala QT); - če imate druge težave s srcem; - če imate v krvi neravnovesje določenih mineralov, na primer kalija in magnezija, zaradi katerega se niste zdravili.
• difficulty urinating 
• oteženo odvajanje vode
0.075 mg) versus intravenous ondansetron. 
palonosetron (1 µg/kg, največji odmerek 0,075 mg) z i.v.
In addition, a majority of patients who entered the main study were followed up for up to 24 months afterwards. 
Poleg tega so večino bolnikov, ki so bili vključeni v glavno študijo, spremljali še največ 24 mesecev.
The medicine is available as tablets (50 mg) and the recommended dose is two tablets twice a day taken with food. 
Na voljo je v obliki tablet (50 mg), priporočeni odmerek pa sta dve tableti dvakrat na dan s hrano.
What measures are being taken to ensure the safe and effective use of Deltyba? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Deltyba?
Tuberculosis is an infection caused by the bacterium Mycobacterium tuberculosis (M. tuberculosis). 
Tuberkuloza je okužba, ki jo povzroča bakterija Mycobacterium tuberculosis (M. tuberculosis).
It is used together with other tuberculosis medicines and only when other standard medicine cannot be used either because the disease is resistant to them or because of their side effects. 
Uporablja se skupaj z drugimi zdravili za zdravljenje tuberkuloze in le takrat, kadar drugih standardnih zdravil ni mogoče uporabiti bodisi zaradi odpornosti bolezni proti njim bodisi zaradi njihovih neželenih učinkov.
Although the main study was of short duration and the follow-up studies had shortcomings, the Agency considered that the effects shown after the initial 2 months of treatment are likely to be sustained for the full treatment duration. 
Čeprav je bila glavna študija kratkoročna in so imele nadaljnje študije pomanjkljivosti, je agencija menila, da se učinki, ki so se pokazali po začetnih dveh mesecih zdravljenja, najverjetneje ohranijo v celotnem obdobju zdravljenja.
Deltyba must not be used in patients who have low levels of albumin (a blood protein). 
Zdravilo Deltyba se ne sme uporabljati pri bolnikih, ki imajo nizke ravni albumina (krvne beljakovine).
The safety profile was considered manageable and several measures were introduced to minimise the risks, including a study to confirm the long-term safety. 
Po njenem mnenju je varnostni profil obvladljiv in uvedenih je bilo več ukrepov za zmanjševanje tveganj, vključno s študijo za potrditev dolgoročne varnosti.
Further information on Deltyba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Deltyba so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The Agency noted that an on-going clinical study will provide confirmation on the long-term effectiveness. 
Agencija je menila, da bo klinična študija, ki trenutno poteka, potrdila dolgoročno učinkovitost.
Treatment with these medicines should continue after Deltyba treatment, as recommended by official guidelines. 
Zdravljenje s temi zdravili se mora nadaljevati po prenehanju zdravljenja z zdravilom Deltyba, kot določajo uradne smernice.
The most common side effects with Deltyba (which may affect more than 1 patient in 10) are nausea, vomiting, headache, insomnia (sleeping problems), dizziness, tinnitus (ringing or buzzing in the ears), blood tests showing low potassium levels in the blood, gastritis (inflammation of the stomach lining), decreased appetite and weakness. 
Najpogostejši neželeni učinki zdravila Deltyba (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) so siljenje na bruhanje, bruhanje, glavobol, nespečnost (težave s spanjem), omotica, tinitus (zvenenje ali šumenje v ušesih), krvni testi, ki kažejo nizke ravni kalija v krvi, gastritis (vnetje želodčne sluznice), zmanjšan tek in šibkost.
Deltyba received a marketing authorisation valid throughout the European Union on 28 April 2014. 
Za zdravilo Deltyba je bilo 28. aprila 2014 izdano dovoljenje za promet, veljavno po vsej EU.
The European Medicines Agency decided that Deltyba's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Deltyba večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Every year, the European Medicines Agency will review any new information that becomes available and this overview will be updated as necessary. 
Evropska agencija za zdravila bo vsako leto ponovno pregledala vse nove podatke, ki bodo na voljo.
Why is Deltyba authorised in the EU? 
Zakaj je bilo zdravilo Deltyba odobreno v EU?
Tuberculosis is rare in the EU, and Deltyba was designated an ‘orphan medicine' (a medicine used in rare diseases) on 1 February 2008. 
Tuberkuloza je v EU redka, zato je bilo zdravilo Deltyba 1. februarja 2008 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
The effects of Deltyba have been looked at in one main study involving 481 adults with tuberculosis resistant to standard treatments. 
Učinke zdravila Deltyba so preučevali v eni glavni študiji s 481 odraslimi s tuberkulozo, ki je odporna proti standardnim zdravilom.
Deltyba is given for 6 months together with other tuberculosis medicines. 
Zdravilo Deltyba se daje šest mesecev skupaj z drugimi zdravili za zdravljenje tuberkuloze.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Deltyba have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Deltyba upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The main measure of effectiveness was the proportion of patients who no longer had the bacteria in their sputum (phlegm). 
Glavno merilo učinkovitosti je bil delež bolnikov, ki v izpljunku (sluzi) niso več imeli bakterij.
What benefits of Deltyba have been shown in studies? 
Kakšne koristi zdravila Deltyba so se pokazale v študijah?
As for all medicines, data on the use of Deltyba are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Deltyba stalno spremljajo.
What is Deltyba and what is it used for? 
Kaj je zdravilo Deltyba in za kaj se uporablja?
An overview of Deltyba and why it is authorised in the EU 
Pregled zdravila Deltyba in zakaj je odobreno v EU
Side effects reported with Deltyba are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Deltyba, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Although the way it works is unclear, delamanid is known to block the production of methoxy-mycolic and ketomycolic acids, two essential components of the cell walls of M. tuberculosis, which will cause the bacteria to die. 
Čeprav delovanje delamanida ni jasno, je znano, da zavira tvorbo metoksi-mikolične in keto-mikolične kisline, dveh najpomembnejših sestavin celičnih sten M. tuberculosis, s čimer povzroči uničenje bakterij.
Deltyba has been given ‘conditional authorisation'. 
Zdravilo Deltyba je pridobilo „pogojno dovoljenje za promet“.
For more information about using Deltyba, see the package leaflet or contact a doctor or pharmacist. 
Za več informacij glede uporabe zdravila Deltyba glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
After the main study had finished, patients had the option to receive treatment with Deltyba for 6 months in an extension study. 
Po zaključku glavne študije so imeli bolniki možnost, da zdravilo Deltyba šest mesecev prejemajo v okviru podaljšane študije.
The company that markets Deltyba will provide educational material for healthcare professionals, explaining how to use the medicine safely to avoid problems such as the development of resistance and side effects on the heart, as well as the risks in pregnancy or women who are breast-feeding. 
Podjetje, ki trži zdravilo Deltyba, bo priskrbelo izobraževalno gradivo za zdravstvene delavce in v njem pojasnilo, kako se zdravilo varno uporablja, da ne pride do težav, kot so pojav odpornosti in neželeni učinki za srce, ter opisalo tveganja pri nosečnicah in doječih materah.
Other information about Deltyba 
Druge informacije o zdravilu Deltyba
It must also not be used in patients who are taking certain other medicines that affect the way Deltyba is broken down in the body. 
Prav tako se ne sme uporabljati pri bolnikih, ki jemljejo nekatera druga zdravila, ki vplivajo na presnovo zdravila Deltyba v telesu.
Since Deltyba has been given conditional authorisation, the company that markets Deltyba will carry out further studies to confirm the long-term effectiveness and safety of Deltyba. 
Ker je zdravilo Deltyba pridobilo pogojno dovoljenje za promet, bo podjetje, ki ga trži, izvedlo nadaljnje študije v podporo dolgoročni učinkovitosti in varnosti zdravila Deltyba.
Deltyba is a medicine that is used in adults with tuberculosis affecting the lung and that is multi-drug resistant (resistant to at least isoniazid and rifampicin, the two standard tuberculosis medicines). 
Deltyba je zdravilo, ki se uporablja pri odraslih s tuberkulozo, ki prizadene pljuča in je odporna proti več zdravilom (odporna najmanj proti izoniazidu in rifampicinu, standardnima zdraviloma za zdravljenje tuberkuloze).
Looking at the results of these follow-up studies together, 2 years after starting treatment 75% of patients who received Deltyba for 6 months or more had no bacteria in their sputum compared with 55% of patients who received Deltyba for 2 months or less. 
Skupni rezultati obeh nadaljnjih študij kažejo, da dve leti po začetku zdravljenja bakterij v izpljunku ni več imelo 75 % bolnikov, ki so prejemali zdravilo Deltyba šest mesecev ali več, in 55 % bolnikov, ki so zdravilo Deltyba prejemali dva meseca ali manj.
What are the risks associated with Deltyba? 
Kakšna tveganja so povezana z zdravilom Deltyba?
After 2 months of treatment more than 40% of the patients who were taking Deltyba no longer had the bacteria in their sputum compared with 30% of the patients who were taking placebo. 
Po dveh mesecih zdravljenja bakterij v izpljunku ni več imelo več kot 40 % bolnikov, ki so jemali zdravilo Deltyba, in 30 % bolnikov, ki so jemali placebo.
It should be used according to official guidelines on treating multi-drug resistant tuberculosis. 
Uporabljati ga je treba v skladu z uradnimi smernicami za zdravljenje tuberkuloze, odporne proti več zdravilom.
The active substance in Deltyba, delamanid, is an antibiotic active against M. tuberculosis. 
Učinkovina zdravila Deltyba, delamanid, je antibiotik, ki učinkuje proti M. tuberculosis.
Patients in the study were given Deltyba or placebo (a dummy treatment) for 2 months in addition to their other treatments. 
Bolniki v študiji so dva meseca poleg drugih zdravil prejemali zdravilo Deltyba ali placebo (zdravilo brez učinkovine).
What information is still awaited for Deltyba? 
Katere informacije o zdravilu Deltyba še pričakujemo?
Deltyba can only be obtained with a prescription and treatment should be started and monitored by a doctor who is experienced in the treatment of multi-drug resistant tuberculosis. 
Predpisovanje in izdaja zdravila Deltyba je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik z izkušnjami z zdravljenjem tuberkuloze, odporne proti več zdravilom.
Furthermore the medical need for new agents to treat multi-drug resistant tuberculosis was highlighted. 
Poleg tega je poudarila medicinsko potrebo po novih zdravilih za zdravljenje tuberkuloze, ki je odporna proti več zdravilom.
Deltyba contains the active substance delamanid. 
Zdravilo Deltyba vsebuje učinkovino delamanid.
The Agency considered that the benefits of Deltyba had been shown for patients with multi-drug resistant tuberculosis affecting the lung. 
Agencija je menila, da so se koristi zdravila Deltyba pokazale pri bolnikih s tuberkulozo, ki je odporna proti več zdravilom in prizadene pljuča.
How is Deltyba used? 
Kako se zdravilo Deltyba uporablja?
How does Deltyba work? 
Kako zdravilo Deltyba deluje?
For the full list of side effects of Deltyba, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Deltyba, glejte navodilo za uporabo.
Further information on Sixmo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/sixmo. 
Nadaljnje informacije o zdravilu Sixmo so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/sixmo.
It contains the active substance buprenorphine. 
Vsebuje učinkovino buprenorfin.
The company will also provide an alert card which patients should carry at all times and show to other healthcare professionals before receiving any medical treatment. 
Prav tako bo zagotovilo opozorilno kartico, ki jo morajo imeti bolniki vedno pri sebi in jo pokazati drugim zdravstvenim delavcem pred začetkom katerega koli zdravljenja.
What measures are being taken to ensure the safe and effective use of Sixmo? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Sixmo?
The European Medicines Agency therefore decided that Sixmo's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Sixmo večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The medicine can therefore be used in a controlled way to help prevent withdrawal symptoms and reduce the urge to misuse other opioids. 
Zdravilo se lahko tako nadzorovano uporablja za preprečevanje odtegnitvenih simptomov in zmanjševanje potrebe po zlorabi drugih opioidov.
Other information about Sixmo 
Druge informacije o zdravilu Sixmo
As for all medicines, data on the use of Sixmo are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Sixmo stalno spremljajo.
The patient receives four implants, which are inserted under local anaesthesia in the inner side of the upper arm and kept in place for 6 months. 
Bolnik prejme štiri implantate, ki se vstavijo pod lokalno anestezijo na notranjo stran nadlahti in so vstavljeni šest mesecev.
Sixmo is an implant used to treat dependence on opioid drugs such as heroin or morphine. 
Sixmo je implantat, ki se uporablja za zdravljenje odvisnosti od opioidov, kot sta heroin in morfin.
An overview of Sixmo and why it is authorised in the EU 
Pregled zdravila Sixmo in zakaj je odobreno v EU
Sixmo is used in adults who are already stable while taking buprenorphine under the tongue (no more than 8 mg/day), and who are also receiving medical, social and psychological support. 
Zdravilo Sixmo se uporablja pri odraslih, ki so že stabilizirani s podjezičnim buprenorfinom (ne več kot 8 mg/dan) ter ki prejemajo tudi medicinsko, socialno in psihološko podporo.
The most common side effects related to the insertion and removal of the implant are pain, itching, bruising, bleeding, reddening of the skin and rash at the site of the implant. 
Najpogostejši neželeni učinki zdravila, povezani z vstavitvijo in odstranitvijo implantata, so bolečina, srbenje, modrice, krvavitev, pordelost kože in izpuščaj na mestu implantata.
What is Sixmo and what is it used for? 
Kaj je zdravilo Sixmo in za kaj se uporablja?
Why is Sixmo authorised in the EU? 
Zakaj je bilo zdravilo Sixmo odobreno v EU?
What are the risks associated with Sixmo? 
Kakšna tveganja so povezana z zdravilom Sixmo?
In addition, the company will conduct a study to investigate breakages and other complications during the insertion and removal of the implants in clinical practice. 
Izvedlo bo tudi študijo, v kateri bo proučilo pretrganine ali druge zaplete med vstavljanjem in odstranjevanjem implantatov v klinični praksi.
What benefits of Sixmo have been shown in studies? 
Kakšne koristi je zdravilo Sixmo izkazalo v študijah?
While the effect of the implants tended to wear off with time in patients not previously treated with buprenorphine, it was maintained in patients who were already stable on low doses of buprenorphine and the use of Sixmo is therefore reserved for these patients. 
Medtem ko se je učinek implantatov sčasoma zmanjšal pri bolnikih, ki predhodno niso bili zdravljeni z buprenorfinom, se je ohranil pri bolnikih, ki so že bili stabilni pri majhnih odmerkih buprenorfina, zato je uporaba zdravila Sixmo rezervirana za te bolnike.
The active substance in Sixmo, buprenorphine, is a partial opioid agonist (which means that it acts like an opioid but less powerfully). 
Učinkovina v zdravilu Sixmo, buprenorfin, je delni opioidni agonist (deluje kot opioid, vendar ni tako močan).
Sixmo must not be used together with medicines known as ‘opioid antagonists' (naltrexone and nalmefene). 
Zdravilo Sixmo se ne sme uporabljati sočasno z zdravili, znanimi kot „antagonisti opioidov“ (naltrekson in nalmefen).
Side effects reported with Sixmo are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Sixmo, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sixmo have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Sixmo upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
For more information about using Sixmo, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Sixmo glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The most common side effects with Sixmo (which may affect up to 1 in 10 people) include headache, constipation and difficulty sleeping. 
Najpogostejši neželeni učinki zdravila Sixmo (ki se lahko pojavijo pri največ 1 bolniku od 10) so glavobol, zaprtje in motnje spanja.
The main studies showed that Sixmo was more effective than placebo and at least as effective as sublingual buprenorphine at treating opioid dependence. 
Glavne študije so pokazale, da je bilo zdravilo Sixmo učinkovitejše od placeba in vsaj enako učinkovito kot podjezični buprenorfin pri zdravljenju odvisnosti od opioidov.
Sixmo must not be used by patients with severe respiratory insufficiency (inability to breathe properly), patients with severe liver problems, and patients who are intoxicated with alcohol or are experiencing alcohol withdrawal symptoms. 
Zdravilo Sixmo se ne sme uporabljati pri bolnikih s hudo respiratorno insuficienco (dihalno stisko), bolnikih s hudo okvaro jeter ter pri bolnikih, ki so pod vplivom alkohola ali imajo simptome odtegnitve alkohola.
In both of these studies, the number of urine tests that were negative for opioid use decreased towards the end of the treatment period, indicating a reduction of the effect of Sixmo over time. 
V obeh študijah se je število urinskih testov, ki so bili negativni na uživanje opioidov, zmanjšalo proti koncu obdobja zdravljenja, kar kaže na zmanjšanje učinka zdravil Sixmo skozi čas.